Published in Proc Natl Acad Sci U S A on January 03, 2006
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci (2010) 1.21
Development, sex steroid regulation, and phenotypic characterization of RFamide-related peptide (Rfrp) gene expression and RFamide receptors in the mouse hypothalamus. Endocrinology (2012) 0.99
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Activation of Neuropeptide FF Receptors by Kisspeptin Receptor Ligands. ACS Med Chem Lett (2010) 0.93
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors. J Biol Chem (2012) 0.88
Hypothalamic inhibition of socio-sexual behaviour by increasing neuroestrogen synthesis. Nat Commun (2014) 0.87
Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. Br J Pharmacol (2012) 0.86
Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chem Neurosci (2012) 0.83
Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. Neuropsychopharmacology (2014) 0.82
Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents. Front Endocrinol (Lausanne) (2014) 0.81
Review: neuroestrogen regulation of socio-sexual behavior of males. Front Neurosci (2014) 0.80
Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation. Front Endocrinol (Lausanne) (2013) 0.80
Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. J Med Chem (2016) 0.79
In Vitro Activities of Kissorphin, a Novel Hexapeptide KiSS-1 Derivative, in Neuronal Cells. J Amino Acids (2012) 0.79
Contribution of GnIH Research to the Progress of Reproductive Neuroendocrinology. Front Endocrinol (Lausanne) (2015) 0.79
Dissecting the Roles of Gonadotropin-Inhibitory Hormone in Mammals: Studies Using Pharmacological Tools and Genetically Modified Mouse Models. Front Endocrinol (Lausanne) (2016) 0.78
The Role of Arginine-Phenylalanine-Amide-Related Peptides in Mammalian Reproduction. Int J Fertil Steril (2015) 0.78
Exogenous and endogenous opioid-induced pain hypersensitivity in different rat strains. Pain Res Manag (2014) 0.77
Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors. J Med Chem (2014) 0.77
Nonpeptide ligands of neuropeptide FF: current status and structural insights. Future Med Chem (2012) 0.77
Identification and functional characterization of the phosphorylation sites of the neuropeptide FF2 receptor. J Biol Chem (2014) 0.77
RF9 Acts as a KISS1R Agonist In Vivo and In Vitro. Endocrinology (2015) 0.77
The Role of Neurotransmitters in Protection against Amyloid- β Toxicity by KiSS-1 Overexpression in SH-SY5Y Neurons. ISRN Neurosci (2013) 0.77
Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities. J Vis Exp (2014) 0.77
Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice. PLoS One (2014) 0.76
Selective mode of action of guanidine-containing non-peptides at human NPFF receptors. J Med Chem (2012) 0.76
Kisspeptin Regulation of Neuronal Activity throughout the Central Nervous System. Endocrinol Metab (Seoul) (2016) 0.76
Proteomic analysis of PKCγ-related proteins in the spinal cord of morphine-tolerant rats. PLoS One (2012) 0.76
Structure-activity studies of RFamide-related peptide-1 identify a functional receptor antagonist and novel cardiac myocyte signaling pathway involved in contractile performance. J Med Chem (2012) 0.75
BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice. Br J Pharmacol (2016) 0.75
The hypothalamic NPVF circuit modulates ventral raphe activity during nociception. Sci Rep (2017) 0.75
The hypothalamic neuropeptide FF network is impaired in hypertensive patients. Brain Behav (2014) 0.75
Neuropeptide Y and gamma-melanocyte stimulating hormone (gamma-MSH) share a common pressor mechanism of action. Endocrine (2009) 0.75
Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages. J Clin Invest (2017) 0.75
A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell (2001) 3.52
Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology (2000) 2.82
Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain (1995) 2.41
New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol (2000) 2.05
Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. J Biol Chem (1992) 1.64
Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci U S A (1985) 1.50
Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem (2000) 1.41
Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci (2001) 1.34
Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport (2003) 1.21
Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem (2001) 1.20
NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci (2001) 1.18
Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther (2001) 1.17
Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J Biol Chem (2000) 1.13
Pleasure into pain: the consequences of long-term opioid use. Addict Behav (2004) 1.09
Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci (2003) 1.05
Clinical experience of long-term treatment with epidural and intrathecal opioids--a nationwide survey. Acta Anaesthesiol Scand (1988) 1.04
Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience (1998) 1.02
Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog Neurobiol (1996) 1.02
Neuropeptide FF, pain and analgesia. Eur J Pharmacol (1998) 1.00
Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem (1999) 1.00
Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur J Pharmacol (2002) 0.99
Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol (1997) 0.95
Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain (1991) 0.95
Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance. Neurosci Biobehav Rev (1999) 0.93
Neuropeptide FF and modulation of pain. Brain Res (1999) 0.91
Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res (1995) 0.88
Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol (2001) 0.87
A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse (1992) 0.87
Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. Peptides (1994) 0.86
Quantitative autoradiographic mapping of delta-opioid receptors in the rat central nervous system using [125I][D.Ala2]deltorphin-I. Synapse (1993) 0.84
Two faces for an opioid peptide--and more receptors for pain research. Nat Neurosci (2002) 0.84
Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience (2002) 0.84
Central administration of neuropeptide FF causes activation of oxytocin paraventricular hypothalamic neurones that project to the brainstem. J Neuroendocrinol (2003) 0.84
Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol (1998) 0.83
FMRF-amide and L-Arg-L-Phe increase blood pressure and heart rate in the anaesthetised rat by central stimulation of the sympathetic nervous system. Biochem Biophys Res Commun (1991) 0.83
Neuropeptide FF receptor 2 (NPFF2) is localized to pain-processing regions in the primate spinal cord and the lower level of the medulla oblongata. J Chem Neuroanat (2003) 0.82
FMRF-NH2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides (1991) 0.82
IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett (1991) 0.81
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptides. Peptides (1998) 0.80
Neuropeptide FF: new molecular insights. Trends Pharmacol Sci (2001) 0.79
Changes in CNS neuropeptide FF-like material, pain sensitivity, and opiate dependence following chronic morphine treatment. Peptides (1995) 0.78
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 4.79
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell (2009) 3.61
Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science (2004) 2.76
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev (2006) 2.57
Reward processing by the opioid system in the brain. Physiol Rev (2009) 2.46
Chemerin--a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun (2007) 2.00
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A (2006) 1.95
Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain (2011) 1.90
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology (2005) 1.88
Detection and enumeration of coliforms in drinking water: current methods and emerging approaches. J Microbiol Methods (2002) 1.79
Natural variation in a neural globin tunes oxygen sensing in wild Caenorhabditis elegans. Nature (2009) 1.73
In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One (2009) 1.70
Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol (2005) 1.70
Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol (2004) 1.69
The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem (2003) 1.67
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci (2011) 1.60
Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci (2003) 1.59
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57
Defective postnatal development of the male reproductive tract in LGR4 knockout mice. Dev Biol (2006) 1.56
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med (2005) 1.54
Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol (2006) 1.54
Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases. Pharmacol Ther (2007) 1.54
Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol (2004) 1.53
Evolution of a novel phenolic pathway for pollen development. Science (2009) 1.50
Predominance of aqueous Tl(I) species in the river system downstream from the abandoned Carnoulès mine (Southern France). Environ Sci Technol (2011) 1.47
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol (2006) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol (2009) 1.45
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem (2007) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 1.41
Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest (2003) 1.40
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell (2002) 1.39
Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther (2007) 1.39
Tonic signaling from O₂ sensors sets neural circuit activity and behavioral state. Nat Neurosci (2012) 1.34
Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci (2002) 1.32
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther (2003) 1.32
Opioid receptors: distinct roles in mood disorders. Trends Neurosci (2012) 1.31
Temperature, oxygen, and salt-sensing neurons in C. elegans are carbon dioxide sensors that control avoidance behavior. Neuron (2011) 1.30
G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol (2003) 1.30
Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol (2008) 1.29
Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharmacol (2008) 1.29
Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev (2011) 1.28
Activation of human dental pulp progenitor/stem cells in response to odontoblast injury. Arch Oral Biol (2005) 1.27
Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci (2003) 1.26
Interaction between hypothalamic dorsomedial nucleus and the suprachiasmatic nucleus determines intensity of food anticipatory behavior. Proc Natl Acad Sci U S A (2011) 1.24
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol (2006) 1.24
Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci (2002) 1.24
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem (2007) 1.23
The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg (2002) 1.22
Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci (2010) 1.21
Identification of a novel family of G protein-coupled receptor associated sorting proteins. J Neurochem (2004) 1.20
Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev (2005) 1.19
Supplementing desflurane-remifentanil anesthesia with small-dose ketamine reduces perioperative opioid analgesic requirements. Anesth Analg (2002) 1.19
The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. Eur J Neurosci (2004) 1.19
Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res (2005) 1.17
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol (2009) 1.15
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med (2004) 1.14
Inflammatory pain is enhanced in delta opioid receptor-knockout mice. Eur J Neurosci (2008) 1.14
Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry (2010) 1.14
Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol (2003) 1.13
Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther (2003) 1.13
Ligand-directed signalling within the opioid receptor family. Br J Pharmacol (2012) 1.13
Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem (2002) 1.13
Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol (2005) 1.12
Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci U S A (2006) 1.12
Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a "thrifty gene". Diabetes (2005) 1.12
Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur J Neurosci (2006) 1.12
Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice. Brain Res (2002) 1.10
Deletion of the δ opioid receptor gene impairs place conditioning but preserves morphine reinforcement. Biol Psychiatry (2010) 1.09
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood (2007) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine. Anesthesiology (2002) 1.09
Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats. Neuropsychopharmacology (2007) 1.09
Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem (2008) 1.08
Zinc alleviates pain through high-affinity binding to the NMDA receptor NR2A subunit. Nat Neurosci (2011) 1.08
Generation and characterization of Rgs4 mutant mice. Mol Cell Biol (2005) 1.08
F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J Immunol (2007) 1.08
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol (2003) 1.06
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci (2002) 1.04
Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem (2002) 1.03
Nociceptin receptor impairs recognition memory via interaction with NMDA receptor-dependent mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in the hippocampus. J Neurosci (2008) 1.03